Patent: 10,898,574
✉ Email this page to a colleague
Summary for Patent: 10,898,574
| Title: | Delivery and formulation of engineered nucleic acids |
| Abstract: | Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins. |
| Inventor(s): | Antonin de Fougerolles, Sayda M. Elbashir |
| Assignee: | ModernaTx Inc |
| Application Number: | US15/927,730 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,898,574
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Biontech Manufacturing Gmbh | COMIRNATY | covid-19 vaccine, mrna | For Injection | 125742 | August 23, 2021 | 10,898,574 | 2038-03-21 |
| Biontech Manufacturing Gmbh | COMIRNATY | covid-19 vaccine, mrna | For Injection | 125742 | September 11, 2023 | 10,898,574 | 2038-03-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,898,574
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2012135805 | ⤷ Start Trial |
| United States of America | 11911474 | ⤷ Start Trial |
| United States of America | 12364763 | ⤷ Start Trial |
| United States of America | 12409226 | ⤷ Start Trial |
| United States of America | 12419957 | ⤷ Start Trial |
| United States of America | 2012251618 | ⤷ Start Trial |
| United States of America | 2013245103 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
